Viktor P.
- Country
- Croatia
- Department
- Cardiology Department
Research Overview
- Inclisiran for Prevention of Major Adverse Cardiovascular Events in High-Risk Primary Prevention Patients with Atherosclerotic Cardiovascular Disease
- Evaluation of Inclisiran's Efficacy in Reducing Major Adverse Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease: A Randomized, Double-Blind, Placebo-Controlled Trial
- Evaluation of Inclisiran in Reducing Major Adverse Cardiovascular Events in High-Risk Primary Prevention of Atherosclerotic Cardiovascular Disease
Data & Insights
Has run more than one trial at 432 of 906 partner sites.
Specializations
Atherosclerotic Cardiovascular Disease Prevention
Viktor Persic is involved in clinical research focused on atherosclerotic cardiovascular disease and primary prevention, with particular interest in reducing major adverse cardiovascular events in people at elevated cardiovascular risk.
- ASCVD
- Primary prevention of cardiovascular events
- Myocardial infarction and stroke prevention
His work in this area reflects a strong therapeutic focus on cardiovascular risk reduction in patients with established vascular disease and those with significant risk factors.
Hypertrophic Cardiomyopathy
His research landscape includes hypertrophic cardiomyopathy, covering both obstructive cardiomyopathy and non-obstructive hypertrophic cardiomyopathy, with attention to symptom burden and functional limitation in affected patients.
- Symptomatic hypertrophic cardiomyopathy
- Obstructive cardiomyopathy
- Non-obstructive hypertrophic cardiomyopathy
This area highlights his involvement in therapies aimed at improving clinical status in structural heart disease.
Type 2 Diabetes and Cardiometabolic Risk
Viktor Persic is active in studies addressing type 2 diabetes, especially when combined with hypertension and established cardiovascular disease, where cardiometabolic therapies are evaluated for their impact on cardiovascular outcomes and glycaemic control.
- Type 2 diabetes
- Hypertension
- Cardiovascular disease with metabolic comorbidity
His trial involvement extends to therapies that target both metabolic regulation and cardiovascular protection in high-risk patients.
Overweight and Obesity Management
His clinical research also covers overweight and obesity, including populations with concurrent type 2 diabetes, with interest in treatments that support body-weight reduction and metabolic improvement.
- Overweight
- Obesity
- Weight management in type 2 diabetes
This domain aligns with broader cardiometabolic care, where excess body weight contributes to cardiovascular and metabolic disease burden.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.